ORIC Pharmaceuticals is advancing ORIC-114 for 1st-line EGFR/HER2 exon 20 NSCLC, with comprehensive data expected in the 2nd ...

"As patients living with EGFR exon 20 insertion-mutated NSCLC face a particularly poor prognosis, the need for innovative combinations in the frontline setting is vital." EGFR mutations are the ...

The drug first came to the market in 2021 as a post-chemo treatment for NSCLC patients with EGFR exon 20 mutations. The new green light comes on the back of the MARIPOSA-2 trial date – reported ...

“Despite an evolving treatment landscape, patients with non-small cell lung cancer with EGFR exon 20 insertion mutations continue to have limited treatment options and poor disease outcomes ...

Cullinan Therapeutics (CGEM) announced that results from the REZILIENT1 study of zipalertinib in non-small cell lung cancer patients with EGFR ...

Pink slips have followed the green light at Entrada Therapeutics. | Pink slips have followed the green light at Entrada ...